BeOne Medicines (formerly BeiGene) and Revolution Medicines are joining forces to test combination therapies against cancers driven by mutations in the notoriously hard-to-drug RAS gene.
Announced August 11, 2026, the deal has two parts: joint clinical studies combining the companies’ drugs in “RAS-addicted” cancers, and a regional rights agreement giving BeOne exclusive development and commercialization rights in select Asian markets (Revolution keeps everything else, including Japan and South Korea). BeOne will fund and run a global Phase 3 registrational trial. Financial terms weren’t disclosed, but the deal includes development milestones and tiered royalties to Revolution.
The drugs
Revolution brings its RAS(ON) inhibitors — daraxonrasib, zoldonrasib, elironrasib and RMC-5127 — a class designed to hit the active form of RAS, a driver of many lung, colorectal and pancreatic cancers that long resisted drugging. BeOne pairs them with assets from its own pipeline, including the PRMT5 inhibitor BGB-58067 and a trispecific antibody, BG-T187.
Why it matters
RAS mutations are among the most common in cancer, and combining a RAS drug with complementary agents is a leading strategy to boost responses and fend off resistance. “This collaboration…gives BeOne the opportunity to evaluate combinations between assets from our oncology pipeline and four promising RAS(ON) inhibitors,” said BeOne CEO John Oyler. For Revolution, it extends its RAS franchise into Asia while a partner shoulders trial costs.